Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease.
In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.
Burt
R K
RK
Northwestern University Medical Center, and the Rupert H. Lurie Cancer Center, Chicago, Illinois, USA.
Brenner
M
M
Burns
W
W
Courier
E
E
Firestein
G
G
Hahn
B
B
Heslop
H
H
Link
C
C
McFarland
H
H
Roland
M
M
Territo
M
M
Tsokos
G
G
Traynor
A
A
D001327:Autoimmune Diseases / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005822:Genetic Vectors; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D014182:Transplantation, Autologous